MicroRNAs as biomarkers for major depression: A role for let-7b and let-7c

Translational Psychiatry

Volumn 6, Issue 8, 2016, Pages

  Gururajan, A ^a   Naughton, M E ^a,b   Scott, K A ^c   O'Connor, R M ^a   Moloney, G ^a   Clarke, G ^a,c   Dowling, J ^a   Walsh, A ^a   Ismail, Muhammad Fahmi ^a   Shorten, G ^a   Scott, L ^a   McLoughlin, D M ^b,d   Cryan, J F ^a,c   Dinan, T G ^a,c  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b St Patrick's University Hospital   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

^d TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; KETAMINE; MICRORNA; MICRORNA 16; MICRORNA 182; MICRORNA 223; MICRORNA 451; MICRORNA LET 7B; MICRORNA LET 7C; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR BLOCKING AGENT; MIRNLET7 MICRORNA, HUMAN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROCONVULSIVE THERAPY; FEMALE; GENE EXPRESSION REGULATION; GENE ONTOLOGY; HAMILTON DEPRESSION RATING SCALE; HUMAN; INFUSION; MAJOR DEPRESSION; MALE; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; CASE CONTROL STUDY; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

ADULT; BIOMARKERS; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; ELECTROCONVULSIVE THERAPY; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MICROARRAY ANALYSIS; MICRORNAS; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84982728594     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2016.131     Document Type: Article

References (57)

1. Lancet T. Depression and the global economic crisis: is there hope Lancet 2012; 380: 1203.
2. Schmidt HD, Shelton RC, Duman RS. Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 2011; 36: 2375-2394.
3. Insel TR. Beyond Efficacy: The STARD Trial. Am J Psychiatry 2006; 163: 5-7.
4. Warden D, Rush AJ, Trivedi M, Fava M, Wisniewski S. The STARD project results: A comprehensive review of findings. Curr Psychiatry Rep 2007; 9: 449-459.
5. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
6. Geaghan M, Cairns MJ. MicroRNA and posttranscriptional dysregulation in psychiatry. Biol Psychiatry 2014; 78: 231-239.
7. Gururajan A, Clarke G, Dinan TG, Cryan JF. Molecular biomarkers of depression. Neurosci Biobehav Rev 2016; 64: 101-133.
8. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
9. Sun W, Julie Li YS, Huang HD, Shyy JY, Chien S. MicroRNA: a master regulator of cellular processes for bioengineering systems. Annu Rev Biomed Eng 2010; 12: 1-27.
10. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56: 1733-1741.
11. Song M-F, Dong J-Z, Wang Y-W, He J, Ju X, Zhang L et al. CSF miR-16 is decreased in major depression patients and its neutralization in rats induces depression-like behaviors via a serotonin transmitter system. J Affect Disord 2015; 178: 25-31.
12. Li YJ, Xu M, Gao ZH, Wang YQ, Yue Z, Zhang YX et al. Alterations of serum levels of BDNF-related miRNAs in patients with depression. PLoS ONE 2013; 8: e63648.
13. Camkurt MA, Acar, Cokun S, Güne M, Güne S, Ylmaz MF et al. Comparison of plasma MicroRNA levels in drug naive, first episode depressed patients and healthy controls. J Psychiatr Res 2015; 69: 67-71.
14. Lopez JP, Lim R, Cruceanu C, Crapper L, Fasano C, Labonte B et al. MiR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment. Nat Med 2014; 20: 764-768.
15. Mouillet-Richard S, Baudry A, Launay J-M, Kellermann O. MicroRNAs and depression. Neurobiol Dis 2012; 46: 272-278.
16. O'Connor RM, Grenham S, Dinan TG, Cryan JF. MicroRNAs as novel antidepressant targets: converging effects of ketamine and electroconvulsive shock therapy in the rat hippocampus. Int J Neuropsychopharmacol 2013; 16: 1885-1892.
17. Yang X, Yang Q, Wang X, Luo C, Wan Y, Li J et al. MicroRNA expression profile and functional analysis reveal that miR-206 is a critical novel gene for the expression of BDNF induced by ketamine. Neuromolecular Med 2014; 16: 594-605.
18. Naughton M, Clarke G, O'Leary OF, Cryan JF, Dinan TG. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and preclinical evidence on proposed mechanisms of action. J Affect Disord 2014; 156: 24-35.
19. Wijkstra J, Nolen WA, Algra A, van Vliet IM, Kahn RS. Relapse prevention in major depressive disorder after successful ECT: a literature review and a naturalistic case series. Acta Psychiatr Scand 2000; 102: 454-460.
20. DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci 2015; 1345: 47-58.
21. Allen AP, Naughton M, Dowling J, Walsh A, Ismail F, Shorten G et al. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT. J Affect Disord 2015; 186: 306-311.
22. Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos IS, Vergoulis T, Reczko M et al. DIANA-microT web server v5. 0: service integration into miRNA functional analysis workflows. Nucleic Acids Res 2013; 41: W169-W173.
23. Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28: 27-30.
24. Vlachos IS, Zagganas K, Paraskevopoulou MD, Georgakilas G, Karagkouni D, Vergoulis T et al. DIANA-miRPath v3. 0: deciphering microRNA function with experimental support. Nucleic Acids Res 2015; 43: W460-W466.
25. Reference Genome Group of the Gene Ontology Consortium. The Gene Ontology's Reference Genome Project: a unified framework for functional annotation across species. PLoS Comput Biol 2009; 5: e1000431.
26. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 2015; 43: D447-D452.
27. Stilling RM, Ryan FJ, Hoban AE, Shanahan F, Clarke G, Claesson MJ et al. Microbes & neurodevelopment-Absence of microbiota during early life increases activityrelated transcriptional pathways in the amygdala. Brain Behav Immun 2015; 50: 209-220.
28. Rehfeld F, Rohde AM, Nguyen DT, Wulczyn FG. Lin28 and let-7: ancient milestones on the road from pluripotency to neurogenesis. Cell Tissue Res 2015; 359: 145-160.
29. Schratt G. MicroRNAs at the synapse. Nat Rev Neurosci 2009; 10: 842-849.
30. Rizos E, Siafakas N, Katsantoni E, Skourti E, Salpeas V, Rizos I et al. Let-7, Mir-98 and Mir-181 as biomarkers for cancer and schizophrenia. PLoS ONE 2015; 10: e0123522.
31. Scott KA, Hoban AE, Clarke G, Moloney GM, Dinan TG, Cryan JF. Thinking small: towards microRNA-based therapeutics for anxiety disorders. Expert Opin Invest Drugs 2015; 24: 529-542.
32. Jernigan CS, Goswami DB, Austin MC, Iyo AH, Chandran A, Stockmeier CA et al. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1774-1779.
33. Chandran A, Iyo AH, Jernigan CS, Legutko B, Austin MC, Karolewicz B. Reduced phosphorylation of the mTOR signaling pathway components in the amygdala of rats exposed to chronic stress. Prog Neuropsychopharmacol Biol Psychiatry 2013; 40: 240-245.
34. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M et al. MTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329: 959-964.
35. Paslakis G, Blum WF, Deuschle M. Intranasal insulin-like growth factor I (IGF-I) as a plausible future treatment of depression. Med Hypotheses 2012; 79: 222-225.
36. Plum L, Schubert M, Brüning JC. The role of insulin receptor signaling in the brain. Trends Endocrinol Metab 2005; 16: 59-65.
37. Bondy CA, Cheng CM. Signaling by insulin-like growth factor 1 in brain. Eur J Pharmacol 2004; 490: 25-31.
38. Mahajan T, Crown A, Checkley S, Farmer A, Lightman S. Atypical depression in growth hormone deficient adults, and the beneficial effects of growth hormone treatment on depression and quality of life. Eur J Endocrinol 2004; 151: 325-332.
39. Birmaher B, Dahl RE, Williamson DE, Perel JM, Brent DA, Axelson DA et al. Growth hormone secretion in children and adolescents at high risk for major depressive disorder. Arch Gen Psychiatry 2000; 57: 867-872.
40. Koenigsberg HW, Teicher MH, Mitropoulou V, Navalta C, New AS, Trestman R et al. 24-h Monitoring of plasma norepinephrine, MHPG, cortisol, growth hormone and prolactin in depression. J Psychiatr Res 2004; 38: 503-511.
41. Franz B, Buysse DJ, Cherry CR, Gray NS, Grochocinski VJ, Frank E et al. Insulin-like growth factor 1 and growth hormone binding protein in depression: a preliminary communication. J Psychiatr Res 1999; 33: 121-127.
42. Herrington J, Carter-Su C. Signaling pathways activated by the growth hormone receptor. Trends Endocrinol Metab 2001; 12: 252-257.
43. Mulder RT, Joyce PR, Frampton C. Relationships among measures of treatment outcome in depressed patients. J Affect Disord 2003; 76: 127-135.
44. Clark CP, Golshan S. Polysomnography and criteria for the antidepressant response to sleep deprivation. J Affect Disord 2007; 101: 195-200.
45. Liew C-C, Ma J, Tang H-C, Zheng R, Dempsey AA. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med 2006; 147: 126-132.
46. Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O. MiR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 2010; 329: 1537-1541.
47. Wang X, Sundquist J, Zöller B, Memon AA, Palmér K, Sundquist K et al. Determination of 14 circulating microRNAs in Swedes and Iraqis with and without diabetes mellitus type 2. PLoS ONE 2014; 9: e86792.
48. Chang X, Li S, Li J, Yin L, Zhou T, Zhang C et al. Ethnic differences in microRNA-375 expression level and DNA methylation status in type 2 diabetes of Han and Kazak populations. J Diabetes Res 2014; 2014: 761938.
49. Rawlings-Goss RA, Campbell MC, Tishkoff SA. Global population-specific variation in miRNA associated with cancer risk and clinical biomarkers. BMC Med Genomics 2014; 7: 53.
50. Malykhin NV, Coupland NJ. Hippocampal neuroplasticity in major depressive disorder. Neuroscience 2015; 309: 200-213.
51. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008; 455: 894-902.
52. Bocchio-Chiavetto L, Maffioletti E, Bettinsoli P, Giovannini C, Bignotti S, Tardito D et al. Blood microRNA changes in depressed patients during antidepressant treatment. Eur Neuropsychopharmacology 2013; 23: 602-611.
53. Wan Y, Liu Y, Wang X, Wu J, Liu K, Zhou J et al. Identification of differential microRNAs in cerebrospinal fluid and serum of patients with major depressive disorder. PLoS ONE 2015; 10: e0121975.
54. Pradervand S, Weber J, Lemoine F, Consales F, Paillusson A, Dupasquier M et al. Concordance among digital gene expression, microarrays, and qPCR when measuring differential expression of microRNAs. Biotechniques 2010; 48: 219-222.
55. Chen Y, Gelfond JA, McManus LM, Shireman PK. Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis. BMC Genomics 2009; 10: 407.
56. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
57. Issler O, Haramati S, Paul ED, Maeno H, Navon I, Zwang R et al. MicroRNA 135 is essential for chronic stress resiliency, antidepressant efficacy, and intact serotonergic activity. Neuron 2014; 83: 344-360.